PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra

PHASE4CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2006

Study Completion Date

December 31, 2006

Conditions
Contraception
Interventions
DRUG

ethinyl estradiol/etonogestrel vaginal ring

vaginal ring for cyclic use (3 weeks in, 1 week out)

DRUG

ethinyl estradiol/norelgestromin transdermal contraceptive

contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval

Trial Locations (10)

15213

Magee-Womens Hospital, Pittsburgh

Unknown

UCLA-Harbor, Los Angeles

University of Chicago, Chicago

Johns Hopkins, Baltimore

Boston University, Boston

Columbia University, New York

Oregon Health Science University, Portland

University of Pennsylvania, Philadelphia

Eastern Virginia Medical School, Norfolk

University of Wisconsin, Madison

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Organon

INDUSTRY

lead

University of Pittsburgh

OTHER

NCT00269620 - PARIS or PAtch RIng Study: A Trial to Evaluate NuvaRing Versus OrthoEvra | Biotech Hunter | Biotech Hunter